{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:45Z","timestamp":1785265125953,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":126,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200624"],"award-info":[{"award-number":["82200624"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,4,18]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Combined-isotype anticardiolipin (aCL) and anti-\u03b22-glycoprotein I (anti-\u03b22GPI) immunoglobulin A, G and M (IgAGM) assays are used in current laboratory practice, but their disease relevance and clinical interpretation remain incompletely defined. This study aimed to establish 99th-percentile reference intervals for aCL IgAGM and anti-\u03b22GPI IgAGM in a large general healthy population and to provide a basis for future disease-oriented evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 7846 eligible individuals who underwent health inspection were included in the analysis. Plasma aCL IgAGM and anti-\u03b22GPI IgAGM were measured by ELISA. A physiologically normal reference subgroup was defined by excluding predefined laboratory abnormalities at the retained index visit (n=989). Retrospective contextual analyses were also performed in systemic lupus erythematosus (SLE) and coronary heart disease (CHD) populations with historical IgAGM results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 7846 individuals (5170 male and 2676 female; age 15\u201390 years), the 99th percentiles were 35.4 relative units (RU)\/mL for aCL and 51.7 RU\/mL for anti-\u03b22GPI. In the physiologically normal reference subgroup, the corresponding values were 23.33 RU\/mL and 46.25 RU\/mL. Sex differences were significant for both antibodies in the overall population and in the physiologically normal subgroup, and aCL showed age-related increases at the upper tail. In retrospective analyses, SLE showed higher proportions above all four cut-offs than CHD, with significance for anti-\u03b22GPI at both the general health participant cut-off (11.4% vs 4.5%, p=0.0425) and the physiologically normal cut-off (12.3% vs 4.5%, p=0.0200). Exploratory analyses linked antibody levels to triglyceride-related profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Assay-specific 99th-percentile reference intervals for aCL IgAGM and anti-\u03b22GPI IgAGM were established in a large health-inspection population and a physiologically normal reference subgroup. These findings provide a practical interpretive framework for combined-isotype assays and support future disease-oriented evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001889","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:15Z","timestamp":1778166915000},"page":"e001889","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Reference intervals for aCL and anti-\u03b22GPI IgAGM antibodies in a large health-inspection population: a foundational study for combined-isotype assay interpretation"],"prefix":"10.1136","volume":"13","author":[{"given":"Guixiang","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6972-8392","authenticated-orcid":false,"given":"Mengyu","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Gong","sequence":"additional","affiliation":[{"name":"General Surgery Department, Chinese PLA General Hospital First Medical Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7096-5497","authenticated-orcid":false,"given":"Heqiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026072811151322000_13.1.e001889.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X"},{"key":"2026072811151322000_13.1.e001889.2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14633"},{"key":"2026072811151322000_13.1.e001889.3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151322000_13.1.e001889.4","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151322000_13.1.e001889.5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2026072811151322000_13.1.e001889.6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082164","article-title":"Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances","volume":"11","author":"Vandevelde","year":"2022","journal-title":"J Clin Med"},{"key":"2026072811151322000_13.1.e001889.7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12537"},{"key":"2026072811151322000_13.1.e001889.8","first-page":"799","article-title":"Anti-cardiolipin and anti-\u03b22-glycoprotein I antibodies: normal reference ranges in northwestern Italy","volume":"21","author":"Montaruli","year":"2012","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151322000_13.1.e001889.9","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1038\/s41598-024-71549-2","article-title":"Establishment of cutoff values for anti-\u03b22 glycoprotein I antibodies in women of reproductive age in Southwest China","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"2026072811151322000_13.1.e001889.10","first-page":"203","article-title":"International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section. The theory of reference values. Part 2. Selection of individuals for the production of reference values","volume":"22","author":"PetitClerc","year":"1984","journal-title":"J Clin Chem Clin Biochem"},{"key":"2026072811151322000_13.1.e001889.11","first-page":"162","article-title":"A guide to IFCC recommendations on reference values","volume":"5","author":"Solberg","year":"1993","journal-title":"J Int Fed Clin Chem"},{"key":"2026072811151322000_13.1.e001889.12","article-title":"Bactrim-Induced Hepatotoxicity","volume":"16","author":"Onyirimba","year":"2024","journal-title":"Cureus"},{"key":"2026072811151322000_13.1.e001889.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.1.178"},{"key":"2026072811151322000_13.1.e001889.14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.5551\/jat.35634","article-title":"Reference Values for The Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Non-High-Density Lipoprotein Cholesterol in Korean Children and Adolescents: The Korean National Health and Nutrition Examination Surveys 2007-2013","volume":"23","author":"Shim","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"2026072811151322000_13.1.e001889.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2026072811151322000_13.1.e001889.16","doi-asserted-by":"crossref","first-page":"110918","DOI":"10.1016\/j.clinbiochem.2025.110918","article-title":"Establishing ELISA-derived 99th percentile reference ranges for aCL and anti-\u03b22GPI antibodies in northern Chinese population: Diagnostic value assessed through P-APS\/SLE case-control study","volume":"137","author":"Shi","year":"2025","journal-title":"Clin Biochem"},{"key":"2026072811151322000_13.1.e001889.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609"},{"key":"2026072811151322000_13.1.e001889.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-6980(99)00010-6"},{"key":"2026072811151322000_13.1.e001889.19","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800155-JLR200"},{"key":"2026072811151322000_13.1.e001889.20","first-page":"736","article-title":"Oxidized LDL\/beta2-glycoprotein I complexes: new aspects in atherosclerosis","volume":"14","author":"Matsuura","year":"2005","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151322000_13.1.e001889.21","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M200329-JLR200"},{"key":"2026072811151322000_13.1.e001889.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100202","article-title":"Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells","volume":"6","author":"Patsouras","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"2026072811151322000_13.1.e001889.23","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.jaut.2022.102978","article-title":"Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome","volume":"134","author":"Verrou","year":"2023","journal-title":"J Autoimmun"},{"key":"2026072811151322000_13.1.e001889.24","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M093112"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:25Z","timestamp":1785262525000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001889"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001889","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}